Expression of Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer: A Meta-Analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 HUYue , YANGShu-yi , Adilijiang ·maimaitiming ,  Dilimulati ·Aisimutula

Department of Breast Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang, China;

Corresponding author：

Dilimulati ·Aisimutula, Email: 602031587@qq.com

Keywords：

Epidermal growth factor receptor; Triple-negative breast cancer; Meta-analysis

DOI：

10.7507/1007-9424.20150389

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore expression of epidermal growth factor receptor(EGFR) in triple-negative breast cancer(TNBC). Method The published articles about expression of EGFR in TNBC according to the inclusion and exclusion criteria from PubMed, Elsevier-Science Direct, and Web of Science databases were retrieved. The meta-analysis was performed with RevMan 5.2 software. Results A total of 8 articles were eligible for the meta-analysis. Among them, 1 006 patients in the TNBC group and 2 945 cases in the non-TNBC group. The result of meta-analysis showed that the positive rate of EGFR expression in the TNBC group was significantly higher than that in the non-TNBC group(OR=6.57, 95% CI 3.42-12.61, P < 0.000 01). The result of race subgroup analysis showed that the positive rate of EGFR expression of TNBC patients in Caucasian(OR=8.93, 95% CI 4.16-19.17, P < 0.000 01) or Xanthoderm(OR=2.79, 95% CI 0.99-7.89, P=0.05) was significantly increased as compared with non-TNBC patients. Conclusion The positive rate of EGFR expression in TNBC patients is higher than that of non-TNBC patients, which might become an important marker of TNBC and an effective therapeutic target.

Citation： HUYue, YANGShu-yi, Adilijiang ·maimaitiming, Dilimulati ·Aisimutula. Expression of Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer: A Meta-Analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(12): 1495-1500. doi: 10.7507/1007-9424.20150389 Copy

1.	IARC. GLOBOCAN 2012: Estimated cancer incidenee, mortality and prevalence worldwide in 2012.(2013-12-1) [2014-1-20]. http://globocan.iarc.Fr/Default.aspx.
2.	芦海亮, 王跃花, 王丽霞, 等.乳腺癌分子分型与临床病理特征的相关性研究.中国药物与临床, 2013, 13(4): 498-499.
3.	Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011, 121(7): 2750-2767.
4.	Steward L, Conant L, Gao F, et al. Predictive factors and patterns of recurrence in patients with triple negative breast cancer. Ann Surg Oncol, 2014, 21(7): 2165-2171.
5.	Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109(1): 25-32.
6.	Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One, 2014, 9(2): e88525.
7.	Tang Y, Zhu L, Li Y, et al. Overexpression of epithelial growth factor receptor(EGFR) predicts better response to neo-adjuvant chemo-therapy in patients with triple-negative breast cancer. J Transl Med, 2012, 10(Suppl 1): S4.
8.	Koo JS, Jung W. Clinicopathlogic and immunohistochemical chara-cteristics of triple negative invasive lobular carcinoma. Yonsei Med J, 2011, 52(1): 89-97.
9.	Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predi-ctor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep, 2009, 21(2): 413-417.
10.	Rydén L, Jirström K, Haglund M, et al. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat, 2010, 120(2): 491-498.
11.	Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer:molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat, 2008, 111(1): 27-44.
12.	Tawfik O, Davis K, Kimler BF, et al. Clinicopathological characteris-tics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women. Ann Clin Lab Sci, 2010, 40(4): 315-323.
13.	Wang XZ, Liu Q, Sun JJ, et al. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. Genet Mol Res, 2015, 14(2): 4282-4290.
14.	Tao JJ, Castel P, Radosevic-Robin N, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal, 2014, 7(318): ra29.
15.	Elbaz M, Nasser MW, Ravi J, et al. Modulation of the tumor microen-vironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol, 2015, 9(4): 906-919.
16.	Maiello MR, Amelia D, Bevilacqua S, et al. EGFR and MEK blockade in triple negative breast cancer cells. J Cell Biochem, 2015 May 8. doi: 10.1002/jcb.25220.[Epubaheadofprint].
17.	Ricciardi GR, Adamo B, Ieni A, et al. Androgen receptor(AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-Negative breast cancer(TNBC) patients. PLoS One, 2015, 10(6): e0128368.
18.	Maeda T, Nakanishi Y, Hirotani Y, et al. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med Mol Morphol, 2015, 2015 May 26.
19.	Anestis A, Karamouzis MV, Dalagiorgou G, et al. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat Rev, 2015, 41(6): 547-553.
20.	Cuenca-López MD, Montero JC, Morales JC, et al. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer, 2014, 14: 302.
21.	Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol, 2009, 20(5): 862-867.
22.	Mancini P, Angeloni A, Risi E, et al. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers(Basel), 2014, 6(4): 2187-2223.
23.	Vora HH, Patel NA, Thakore PM, et al. Immunohistochemical localization of wild-type EGFR, E746-A750 frame deletion in Exon 19, and L858R point mutation in Exon 21 in triple-negative breast cancer. Appl Immunohistochem Mol Morphol, 2015 Mar 16.
24.	袁礼, 吴焕文, 任新瑜, 等.三阴乳腺癌与非三阴乳腺癌临床病理特征差异及与雌激素受体β和表皮生长因子受体表达的关系.协和医学杂志, 2015, (1): 1-8.
25.	Montagna E, Cancello G, Bagnardi V, et al. Metronomic chemo-therapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer, 2012, 12(3): 207-214.
26.	Sobande F, Dušek L, Matějková A, et al. EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number. Cesk Patol, 2015, 51(2): 80-86.
27.	Sersh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with doeetaxel versus docetaxel alone: results of a prospective, randomized phaseⅢstudy. J Clin Oncol, 2012, 30(9): 921-929.
28.	Crown JP, Diéras V, Staroslawska E, et al. PhaseⅢtrial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol, 2013, 31(23): 2870-2878.

1. IARC. GLOBOCAN 2012: Estimated cancer incidenee, mortality and prevalence worldwide in 2012.(2013-12-1) [2014-1-20]. http://globocan.iarc.Fr/Default.aspx.
2. 芦海亮, 王跃花, 王丽霞, 等.乳腺癌分子分型与临床病理特征的相关性研究.中国药物与临床, 2013, 13(4): 498-499.
3. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011, 121(7): 2750-2767.
4. Steward L, Conant L, Gao F, et al. Predictive factors and patterns of recurrence in patients with triple negative breast cancer. Ann Surg Oncol, 2014, 21(7): 2165-2171.
5. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109(1): 25-32.
6. Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One, 2014, 9(2): e88525.
7. Tang Y, Zhu L, Li Y, et al. Overexpression of epithelial growth factor receptor(EGFR) predicts better response to neo-adjuvant chemo-therapy in patients with triple-negative breast cancer. J Transl Med, 2012, 10(Suppl 1): S4.
8. Koo JS, Jung W. Clinicopathlogic and immunohistochemical chara-cteristics of triple negative invasive lobular carcinoma. Yonsei Med J, 2011, 52(1): 89-97.
9. Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predi-ctor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep, 2009, 21(2): 413-417.
10. Rydén L, Jirström K, Haglund M, et al. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat, 2010, 120(2): 491-498.
11. Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer:molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat, 2008, 111(1): 27-44.
12. Tawfik O, Davis K, Kimler BF, et al. Clinicopathological characteris-tics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women. Ann Clin Lab Sci, 2010, 40(4): 315-323.
13. Wang XZ, Liu Q, Sun JJ, et al. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. Genet Mol Res, 2015, 14(2): 4282-4290.
14. Tao JJ, Castel P, Radosevic-Robin N, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal, 2014, 7(318): ra29.
15. Elbaz M, Nasser MW, Ravi J, et al. Modulation of the tumor microen-vironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol, 2015, 9(4): 906-919.
16. Maiello MR, Amelia D, Bevilacqua S, et al. EGFR and MEK blockade in triple negative breast cancer cells. J Cell Biochem, 2015 May 8. doi: 10.1002/jcb.25220.[Epubaheadofprint].
17. Ricciardi GR, Adamo B, Ieni A, et al. Androgen receptor(AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-Negative breast cancer(TNBC) patients. PLoS One, 2015, 10(6): e0128368.
18. Maeda T, Nakanishi Y, Hirotani Y, et al. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med Mol Morphol, 2015, 2015 May 26.
19. Anestis A, Karamouzis MV, Dalagiorgou G, et al. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat Rev, 2015, 41(6): 547-553.
20. Cuenca-López MD, Montero JC, Morales JC, et al. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer, 2014, 14: 302.
21. Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol, 2009, 20(5): 862-867.
22. Mancini P, Angeloni A, Risi E, et al. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers(Basel), 2014, 6(4): 2187-2223.
23. Vora HH, Patel NA, Thakore PM, et al. Immunohistochemical localization of wild-type EGFR, E746-A750 frame deletion in Exon 19, and L858R point mutation in Exon 21 in triple-negative breast cancer. Appl Immunohistochem Mol Morphol, 2015 Mar 16.
24. 袁礼, 吴焕文, 任新瑜, 等.三阴乳腺癌与非三阴乳腺癌临床病理特征差异及与雌激素受体β和表皮生长因子受体表达的关系.协和医学杂志, 2015, (1): 1-8.
25. Montagna E, Cancello G, Bagnardi V, et al. Metronomic chemo-therapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer, 2012, 12(3): 207-214.
26. Sobande F, Dušek L, Matějková A, et al. EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number. Cesk Patol, 2015, 51(2): 80-86.
27. Sersh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with doeetaxel versus docetaxel alone: results of a prospective, randomized phaseⅢstudy. J Clin Oncol, 2012, 30(9): 921-929.
28. Crown JP, Diéras V, Staroslawska E, et al. PhaseⅢtrial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol, 2013, 31(23): 2870-2878.

Previous Article
腹腔镜胆囊切除术后可吸收生物夹排异致黄疸1例报道
Next Article
Fever as Initial Symptom of Intrahepatic Cholangiocellular Carcinoma: Report of 4 Cases

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content